

Nicotinell

PRESCRIBE NICOTINELL TODAY
Help your patients quit¹



**NICOTINELL'S COMPLETE 3-STEP QUIT PROGRAM IS
NOW LISTED ON THE PBS**

AVAILABLE JANUARY 2012 AUTHORITY REQUIRED

4 EASY STEPS TO PRESCRIBE NICOTINELL AND HELP YOUR PATIENTS QUIT:

1. Identify a patient ready to quit
2. Recommend a patient support program: **Call 13 QUIT**
3. Call for Authority
4. Prescribe Nicotinell Step 1, Step 2 or Step 3 as appropriate:
 - Quantity: 28 patches
 - Maximum: 12 weeks treatment
 - Restriction: 1 course per annum

PBS Information: Authority required for the treatment of smoking cessation. Nicotinell® Step 1 patch 21 mg/24hours, Nicotinell® Step 2 patch 14 mg/24 hours, Nicotinell® Step 3 patch 7 mg/24 hours. Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who: has entered a comprehensive support and counselling program; or is entering a comprehensive support and counselling program during the consultation at which the authority is requested. Details of the program must be specified in the initial authority application.

NOTE: A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities will be authorised. Maximum quantity: 28 patches.

PLEASE REVIEW APPROVED PRODUCT INFORMATION (PI) FOR NICOTINELL PATCH BEFORE PRESCRIBING. THE FULL PI IS AVAILABLE FROM NOVARTIS CONSUMER HEALTH AUSTRALASIA, MELBOURNE ON REQUEST.

Nicotinell® Step 1 patch contains nicotine 52.5 mg (release rate 21 mg over 24 hour period). Nicotinell® Step 2 patch contains nicotine 35 mg (release rate 14 mg over 24 hour period). Nicotinell® Step 3 patch contains nicotine 17.5 mg (release rate 7 mg over 24 hour period). **Use:** Treatment of nicotine dependence, as an aid to smoking cessation. **Contraindications:** Non-smokers, children under 12 years, occasional smokers, those with diseases of the skin or hypersensitivity to nicotine or any of the excipients. **Precautions:** Patients with a recent myocardial infarction, angina pectoris, severe cardiac arrhythmias, uncontrolled or severe hypertension, recent cerebrovascular accident, cerebrovascular disease, occlusive peripheral arterial disease, heart failure, hyperthyroidism, pheochromocytoma, moderate to severe hepatic or renal impairment. Monitor blood sugar levels more closely than usual for smokers with diabetes mellitus. Use with caution in patients who are susceptible to angioedema and/or urticaria. Refer to PI for use in pregnancy and breast feeding. **Adverse events:** Commonly reported adverse events and withdrawal symptoms include application site reactions, headache, cold and flu like symptoms, dysmenorrhoea, insomnia, nausea, myalgia and dizziness. **Dosage:** Apply one patch to a clean, non-hairy, dry area of intact skin on the trunk or upper arm. Replace patch after 24 hours, using a different site of application. **Reference:** 1. Nicotinell Product Information. Novartis Consumer Health Australasia Pty Ltd. Melbourne. ABN 46 004 535 513 © Registered trademark. For sales enquiries phone 1300 667 558. NVT1409 NICGPPBS1